Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest update is out from Hansoh Pharmaceutical Group Company Limited ( (HK:3692) ).
Hansoh Pharmaceutical Group Company Limited has entered into a license agreement with Regeneron Pharmaceuticals, Inc., granting Regeneron an exclusive worldwide license to develop, manufacture, and commercialize the investigational drug HS-20094 outside of the Chinese Mainland, Hong Kong, and Macau. This agreement could potentially bring Hansoh up to $1.93 billion in milestone payments and double-digit royalties, enhancing its market position and leveraging its technology platforms. The agreement is seen as beneficial for Hansoh’s shareholders and aligns with the company’s strategic goals.
The most recent analyst rating on (HK:3692) stock is a Buy with a HK$22.06 price target. To see the full list of analyst forecasts on Hansoh Pharmaceutical Group Company Limited stock, see the HK:3692 Stock Forecast page.
More about Hansoh Pharmaceutical Group Company Limited
Hansoh Pharmaceutical Group Company Limited is a pharmaceutical company incorporated in the Cayman Islands, focusing on developing and commercializing innovative medicines. The company operates in the biotechnology sector, primarily dealing with investigational drugs and therapies, with a significant focus on the Chinese market.
Average Trading Volume: 12,253,944
Technical Sentiment Signal: Buy
Current Market Cap: HK$153.7B
See more data about 3692 stock on TipRanks’ Stock Analysis page.